Zaza Mtine Ndhlovu, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
CD8-Positive T-Lymphocytes | 19 | 2022 | 4648 | 1.990 |
Why?
|
HIV-1 | 25 | 2024 | 6951 | 1.970 |
Why?
|
HIV Infections | 34 | 2024 | 17542 | 1.870 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 4 | 2018 | 213 | 1.240 |
Why?
|
Immunologic Memory | 4 | 2022 | 1377 | 1.130 |
Why?
|
Viral Load | 13 | 2020 | 3385 | 1.000 |
Why?
|
Coronavirus NL63, Human | 1 | 2024 | 4 | 0.920 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2022 | 4405 | 0.780 |
Why?
|
AIDS Vaccines | 3 | 2020 | 900 | 0.760 |
Why?
|
HLA-B Antigens | 2 | 2018 | 330 | 0.650 |
Why?
|
Duodenum | 1 | 2022 | 495 | 0.620 |
Why?
|
Lymph Nodes | 4 | 2024 | 3468 | 0.620 |
Why?
|
Lymph Node Excision | 1 | 2024 | 1267 | 0.600 |
Why?
|
HIV | 3 | 2022 | 1591 | 0.600 |
Why?
|
Measles virus | 4 | 2009 | 67 | 0.550 |
Why?
|
Measles Vaccine | 4 | 2009 | 79 | 0.480 |
Why?
|
Lymphocyte Activation | 3 | 2022 | 5499 | 0.480 |
Why?
|
Gene Products, gag | 2 | 2015 | 318 | 0.470 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2018 | 2568 | 0.450 |
Why?
|
Antibody Formation | 1 | 2018 | 1392 | 0.440 |
Why?
|
Antigens, Viral | 3 | 2019 | 994 | 0.430 |
Why?
|
Immunodominant Epitopes | 2 | 2015 | 244 | 0.430 |
Why?
|
Th1 Cells | 1 | 2018 | 1040 | 0.430 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2017 | 1442 | 0.410 |
Why?
|
HIV Antibodies | 2 | 2022 | 1340 | 0.400 |
Why?
|
Immunologic Surveillance | 1 | 2012 | 92 | 0.400 |
Why?
|
Models, Immunological | 1 | 2012 | 516 | 0.350 |
Why?
|
Viremia | 3 | 2020 | 726 | 0.340 |
Why?
|
CD4 Lymphocyte Count | 3 | 2018 | 2586 | 0.330 |
Why?
|
Leukocytes, Mononuclear | 4 | 2024 | 1854 | 0.320 |
Why?
|
Antigen Presentation | 2 | 2011 | 1250 | 0.310 |
Why?
|
T-Lymphocytes | 3 | 2024 | 10254 | 0.310 |
Why?
|
Immunoglobulin G | 2 | 2018 | 4560 | 0.300 |
Why?
|
Blood | 1 | 2009 | 596 | 0.270 |
Why?
|
Measles | 4 | 2009 | 180 | 0.260 |
Why?
|
Antigen-Presenting Cells | 1 | 2009 | 960 | 0.250 |
Why?
|
South Africa | 3 | 2024 | 1873 | 0.240 |
Why?
|
Interferon-gamma | 5 | 2019 | 3154 | 0.230 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 4572 | 0.210 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2022 | 93 | 0.200 |
Why?
|
Receptors, CXCR5 | 1 | 2022 | 88 | 0.200 |
Why?
|
Acute Disease | 5 | 2020 | 7236 | 0.190 |
Why?
|
T-Lymphocytes, Cytotoxic | 3 | 2020 | 1801 | 0.190 |
Why?
|
HLA-A2 Antigen | 3 | 2010 | 207 | 0.180 |
Why?
|
Cytokines | 3 | 2024 | 7446 | 0.170 |
Why?
|
Lymphocyte Count | 1 | 2022 | 793 | 0.170 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2022 | 381 | 0.170 |
Why?
|
Germinal Center | 1 | 2022 | 379 | 0.160 |
Why?
|
Humans | 41 | 2024 | 767040 | 0.160 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 50 | 0.160 |
Why?
|
Zambia | 8 | 2009 | 273 | 0.150 |
Why?
|
Enzyme-Linked Immunospot Assay | 2 | 2015 | 126 | 0.150 |
Why?
|
Kinetics | 2 | 2015 | 6287 | 0.130 |
Why?
|
Young Adult | 7 | 2024 | 59980 | 0.120 |
Why?
|
Clone Cells | 1 | 2018 | 1669 | 0.120 |
Why?
|
Flow Cytometry | 2 | 2015 | 5891 | 0.120 |
Why?
|
History, 21st Century | 1 | 2020 | 1574 | 0.110 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1560 | 0.110 |
Why?
|
Mutation | 1 | 2018 | 30211 | 0.110 |
Why?
|
Adult | 15 | 2024 | 223317 | 0.110 |
Why?
|
Transcriptional Activation | 1 | 2019 | 1751 | 0.100 |
Why?
|
Cell Differentiation | 2 | 2022 | 11657 | 0.100 |
Why?
|
Cell Communication | 1 | 2020 | 1660 | 0.100 |
Why?
|
History, 20th Century | 1 | 2020 | 2765 | 0.100 |
Why?
|
HLA-B27 Antigen | 1 | 2012 | 66 | 0.100 |
Why?
|
Female | 20 | 2024 | 396660 | 0.100 |
Why?
|
Viral Matrix Proteins | 2 | 2010 | 193 | 0.090 |
Why?
|
Male | 16 | 2024 | 364203 | 0.090 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 2011 | 0.090 |
Why?
|
Gene Frequency | 1 | 2017 | 3621 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2016 | 1362 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2850 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1787 | 0.080 |
Why?
|
Cross Reactions | 1 | 2011 | 828 | 0.080 |
Why?
|
RNA, Viral | 2 | 2015 | 2867 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6310 | 0.080 |
Why?
|
HLA-A Antigens | 1 | 2009 | 223 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1405 | 0.080 |
Why?
|
B-Lymphocytes | 1 | 2022 | 4787 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2022 | 3114 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2538 | 0.080 |
Why?
|
Lymphocytes | 1 | 2016 | 2605 | 0.070 |
Why?
|
Hemagglutinins, Viral | 1 | 2007 | 66 | 0.070 |
Why?
|
Amino Acid Sequence | 1 | 2018 | 13411 | 0.070 |
Why?
|
Adenoviridae | 1 | 2011 | 1092 | 0.070 |
Why?
|
Intestines | 1 | 2016 | 1905 | 0.070 |
Why?
|
Species Specificity | 1 | 2011 | 2412 | 0.070 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2007 | 71 | 0.070 |
Why?
|
Immunoglobulins | 1 | 2010 | 853 | 0.070 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 6067 | 0.060 |
Why?
|
Alleles | 1 | 2017 | 6893 | 0.060 |
Why?
|
Epitopes | 2 | 2022 | 2526 | 0.060 |
Why?
|
Immunoassay | 1 | 2009 | 744 | 0.060 |
Why?
|
Phylogeny | 2 | 2023 | 2840 | 0.060 |
Why?
|
Epitopes, T-Lymphocyte | 3 | 2017 | 827 | 0.060 |
Why?
|
Cells, Cultured | 4 | 2017 | 18989 | 0.060 |
Why?
|
Adolescent | 7 | 2020 | 89046 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2019 | 10455 | 0.050 |
Why?
|
Apoptosis | 2 | 2016 | 9513 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8890 | 0.050 |
Why?
|
Time Factors | 6 | 2016 | 40154 | 0.050 |
Why?
|
Proviruses | 1 | 2024 | 319 | 0.050 |
Why?
|
Anti-HIV Agents | 1 | 2017 | 4567 | 0.050 |
Why?
|
Genetic Vectors | 1 | 2011 | 3402 | 0.050 |
Why?
|
Antibodies, Viral | 4 | 2022 | 3212 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20169 | 0.050 |
Why?
|
Sex Distribution | 2 | 2004 | 2276 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16718 | 0.050 |
Why?
|
Age Distribution | 2 | 2004 | 2870 | 0.040 |
Why?
|
Acute-Phase Reaction | 1 | 2020 | 91 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13646 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2040 | 0.040 |
Why?
|
Middle Aged | 5 | 2024 | 223233 | 0.040 |
Why?
|
DNA Methylation | 1 | 2013 | 4426 | 0.040 |
Why?
|
Dendritic Cells | 1 | 2010 | 2745 | 0.040 |
Why?
|
Systems Integration | 1 | 2020 | 425 | 0.040 |
Why?
|
Disease Outbreaks | 2 | 1998 | 1761 | 0.040 |
Why?
|
Peptides | 1 | 2010 | 4348 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2201 | 0.030 |
Why?
|
Virus Replication | 2 | 2016 | 2457 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2016 | 1902 | 0.030 |
Why?
|
Risk-Taking | 1 | 2001 | 1023 | 0.030 |
Why?
|
Infant | 5 | 2009 | 36485 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 14672 | 0.030 |
Why?
|
Base Sequence | 1 | 2024 | 12414 | 0.030 |
Why?
|
Perforin | 1 | 2012 | 167 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14766 | 0.020 |
Why?
|
HIV Long-Term Survivors | 1 | 2012 | 140 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2017 | 4167 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2020 | 1752 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2001 | 2196 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2209 | 0.020 |
Why?
|
Immunoglobulin Isotypes | 1 | 2009 | 158 | 0.020 |
Why?
|
Antibody Affinity | 1 | 2009 | 251 | 0.020 |
Why?
|
Endemic Diseases | 1 | 2009 | 190 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168965 | 0.020 |
Why?
|
Sentinel Surveillance | 2 | 2001 | 292 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7848 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 1998 | 2183 | 0.020 |
Why?
|
Child, Preschool | 2 | 2009 | 42606 | 0.020 |
Why?
|
Immunization, Secondary | 1 | 2007 | 373 | 0.010 |
Why?
|
Gene Expression | 1 | 2017 | 7587 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9532 | 0.010 |
Why?
|
Cell Movement | 1 | 2016 | 5203 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2016 | 3076 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2016 | 3070 | 0.010 |
Why?
|
United States | 1 | 2011 | 72971 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5796 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2008 | 1354 | 0.010 |
Why?
|
Chronic Disease | 1 | 2016 | 9362 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7611 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11923 | 0.010 |
Why?
|
Prevalence | 3 | 2001 | 15851 | 0.010 |
Why?
|
Vaccination | 1 | 2009 | 3434 | 0.010 |
Why?
|
AIDS Serodiagnosis | 1 | 1998 | 220 | 0.010 |
Why?
|
Sampling Studies | 1 | 1998 | 614 | 0.010 |
Why?
|
Child | 1 | 2004 | 80771 | 0.010 |
Why?
|
Saliva | 1 | 1998 | 853 | 0.010 |
Why?
|
Cohort Studies | 1 | 2016 | 41718 | 0.010 |
Why?
|
Prospective Studies | 1 | 2017 | 54886 | 0.010 |
Why?
|
Demography | 1 | 1997 | 1641 | 0.010 |
Why?
|
Educational Status | 1 | 1998 | 2511 | 0.010 |
Why?
|
Prenatal Care | 1 | 1998 | 1158 | 0.010 |
Why?
|
Urban Population | 1 | 1998 | 2044 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2016 | 65295 | 0.000 |
Why?
|
Rural Population | 1 | 1998 | 2321 | 0.000 |
Why?
|
Risk Factors | 1 | 2008 | 74886 | 0.000 |
Why?
|
Age Factors | 1 | 1997 | 18401 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2001 | 39317 | 0.000 |
Why?
|
Pregnancy | 1 | 1998 | 30238 | 0.000 |
Why?
|